Title |
Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles
|
---|---|
Published in |
Breast Cancer Research, December 2011
|
DOI | 10.1186/bcr3079 |
Pubmed ID | |
Authors |
William Jacot, Evelyne Lopez-Crapez, Simon Thezenas, Romain Senal, Frédéric Fina, Frédéric Bibeau, Gilles Romieu, Pierre-Jean Lamy |
Abstract |
Triple-negative breast cancers (TNBCs) are characterised by lack of expression of hormone receptors and epidermal growth factor receptor 2 (HER-2). As they frequently express epidermal growth factor receptors (EGFRs), anti-EGFR therapies are currently assessed for this breast cancer subtype as an alternative to treatments that target HER-2 or hormone receptors. Recently, EGFR-activating mutations have been reported in TNBC specimens in an East Asian population. Because variations in the frequency of EGFR-activating mutations in East Asians and other patients with lung cancer have been described, we evaluated the EGFR mutational profile in tumour samples from European patients with TNBC. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Portugal | 1 | 2% |
Germany | 1 | 2% |
Turkey | 1 | 2% |
United States | 1 | 2% |
Serbia | 1 | 2% |
Unknown | 44 | 90% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 9 | 18% |
Student > Ph. D. Student | 6 | 12% |
Student > Postgraduate | 6 | 12% |
Student > Master | 5 | 10% |
Student > Doctoral Student | 3 | 6% |
Other | 10 | 20% |
Unknown | 10 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 15 | 31% |
Agricultural and Biological Sciences | 12 | 24% |
Biochemistry, Genetics and Molecular Biology | 9 | 18% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
Chemistry | 1 | 2% |
Other | 0 | 0% |
Unknown | 11 | 22% |